Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVTU5Q)

Drug Name

Delafloxacin Meglumine Drug Info

Synonyms

Baxdela

Indication

Disease Entry	ICD 11	Status	REF
Acute bacterial skin infection	1C41	Approved	[1]
Skin infection	1F28-1G0Z	Approved	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Staphylococcus Topoisomerase IV (Stap-coc parC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[3]
Levofloxacin	DMS60RB	Acute maxillary sinusitis		Approved	[3]
Gatifloxacin	DMSL679	Acute gonococcal cervicitis		Approved	[3]
Ozenoxacin	DM6KZMG	Impetigo	1B72	Approved	[4]
Sparfloxacin	DMB4HCT	Bacterial infection	1A00-1C4Z	Approved	[3]
Gemifloxacin	DMHT34O	Bacterial infection	1A00-1C4Z	Approved	[3]
Besifloxacin	DMPHXMI	Ocular inflammation	9C61.24	Approved	[5]
Finafloxacin	DMZEONG	Urinary tract infection	GC08	Approved	[6]
Moxifloxacin	DMU8V4S	Bacterial infection	1A00-1C4Z	Approved	[3]
Zabofloxacin	DMEY1F3	Pneumonia	CA40	Phase 3	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasmodium DNA gyrase (Malaria gyrase)	TTZ82MR	Q8I0X3_PLAF7	Inhibitor	[2]
Staphylococcus Topoisomerase IV (Stap-coc parC)	TTIXTO3	PARC_STAAS	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
2	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
5	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
6	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
7	DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.